{"id":469446,"date":"2026-05-05T11:57:16","date_gmt":"2026-05-05T11:57:16","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/469446\/"},"modified":"2026-05-05T11:57:16","modified_gmt":"2026-05-05T11:57:16","slug":"rare-skin-condition-patients-gain-access-to-new-treatment","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/469446\/","title":{"rendered":"Rare skin condition patients gain access to new treatment"},"content":{"rendered":"<p>The first authorised treatment for a painful and incurable skin condition has been made available in Ireland, in what has been described as a &#8220;transformative moment&#8221;.<\/p>\n<p>Debra, the national charity and patient support organisation for people living with epidermolysis bullosa (EB), described the HSE&#8217;s move to make Filsuvez available as an important step to ease the lives of 300 people battling the illness, also known as butterfly skin.<\/p>\n<p>EB is caused by an absence of proteins between skin layers, meaning skin becomes ultra fragile and blisters at the mildest touch.<\/p>\n<p>The new gel treatment, called Filsuvez, promotes the healing of wounds associated with dystrophic and junctional EB and will be accessible to those prescribed it by their consultant.<\/p>\n<p>It is applied to a sterile, non-adhesive wound dressing or directly to the skin and can reduce the frequency of bandage changes and ease the pain of wounds.<\/p>\n<p>The HSE has agreed to pay all or most of the cost of the drug, depending on what scheme patients qualify for.<\/p>\n<p>Debra chief executive Jimmy Fearon said introducing Filsuvez &#8220;is a promising start, as it can offer temporary pain relief, and we hope it will mark the beginning for the treatment of EB in Ireland&#8221;.<\/p>\n<p>&#8220;This has been a long journey and marks a transformative moment for people living with this rare skin condition,&#8221; he said.<\/p>\n<p>Last year, the National Centre for Pharmacoeconomics (NCPE) recommended that the gel, developed by pharma group Chiesi, be considered for what is known as reimbursement.<\/p>\n<p>Mr Fearon said the charity hopes it is the beginning of EB-specific medicine reimbursement in this country.<\/p>\n<p>&#8220;This decision represents hope, dignity and meaningful progress for EB patients and their families,&#8221; he said.<\/p>\n<p>&#8220;For too long, people living with EB have had no approved treatment options.<\/p>\n<p>&#8220;Ireland is in the lowest quartile in Europe for introducing new drugs to the market.<\/p>\n<p>&#8220;The average timeline from European Medicines Agency decision to reimbursement in this country is 1,024 days, far beyond the 611-day average in the rest of Europe.<\/p>\n<p>&#8220;The HSE&#8217;s commitment to reimburse Filsuvez is a powerful acknowledgement of the urgent unmet need within this community.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"The first authorised treatment for a painful and incurable skin condition has been made available in Ireland, in&hellip;\n","protected":false},"author":2,"featured_media":469447,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[9,10,18,13,14,6,19,17,11,12,15,16,5,7,8],"class_list":{"0":"post-469446","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-headlines","8":"tag-breaking-news","9":"tag-breakingnews","10":"tag-eire","11":"tag-featured-news","12":"tag-featurednews","13":"tag-headlines","14":"tag-ie","15":"tag-ireland","16":"tag-latest-news","17":"tag-latestnews","18":"tag-main-news","19":"tag-mainnews","20":"tag-news","21":"tag-top-stories","22":"tag-topstories"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/116521851045327601","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/469446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=469446"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/469446\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/469447"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=469446"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=469446"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=469446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}